Biocartis, Exploit Technologies Ink MDx Assay Development Deal

Jul 10, 2017

NEW YORK (GenomeWeb) – Biocartis announced today that it has extended its partnership with Exploit Technologies (ETPL) — the commercialization arm of Singapore's Agency for Science, Technology, and Research — to develop molecular diagnostic assays, including one for breast cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Featured White Papers

ABBOTT Informatics STARLIMS Solution Helps Precision Diagnostics Achieve Compliance and Retain Customers

Discovering Neuronal Cell Types

Immuno-Oncology: 3 Strategies for Applying Humanized Models

A Guide to Selecting Your Next Immuno-Oncology Model

Jun

26

Featured Webinar

The Landscape of Alternative Polyadenylation in the Lung Cancer Transcriptome

This webinar outlines a study that sought to characterize the landscape of alternative polyadenylation (APA) in the lung cancer transcriptome in order to gain insight into the role of APA in cancer progression.

Jul

10

Featured Webinar

Case Study: Genetic Testing Lab Sees 25-Fold Scaleup with New Informatics System

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Jul

19

Featured Webinar

Advances in NGS for Ultra-High Sensitivity Applications in Translational and Clinical Research

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.

Jul

25

Featured Webinar

Antibiotic Gene Surveillance: What You Don’t See Can Hurt You!

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms.

Main menu